Aris­tea shut­ters, end­ing hopes of a Pfiz­er buy­out

As­traZeneca spin­out Aris­tea Ther­a­peu­tics is shut­ting down af­ter ter­mi­nat­ing mul­ti­ple Phase II stud­ies of its in­flam­ma­to­ry drug, cit­ing undis­closed safe­ty is­sues.

With the culling of mul­ti­ple mid-stage tests of the in­ves­ti­ga­tion­al drug RIST4721, “to pro­tect pa­tient safe­ty,” Aris­tea said Fri­day its board con­sid­ered “a range of strate­gic al­ter­na­tives” and de­cid­ed to turn off the lights on the 12-em­ploy­ee San Diego biotech.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER